Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.60, $0.49 better than the analyst estimate of $0.11. Revenue for the quarter came in at $234.3 million versus the consensus estimate of $186 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.